[HTML][HTML] B-cell activating factor targeted therapy and lupus
A Boneparth, A Davidson - Arthritis research & therapy, 2012 - Springer
A Boneparth, A Davidson
Arthritis research & therapy, 2012•SpringerB-cell activating factor (BAFF), a member of the family of TNF-like cytokines, supports the
survival and differentiation of B cells. The successful development of belimumab, a human
antibody targeting soluble BAFF, has marked an important milestone in the development of
biologic therapy for treatment of systemic lupus erythematosus (SLE), although much
remains unknown regarding the clinical utility of BAFF inhibition in SLE and other
autoimmune diseases. In the present review, we provide an overview of the knowledge …
survival and differentiation of B cells. The successful development of belimumab, a human
antibody targeting soluble BAFF, has marked an important milestone in the development of
biologic therapy for treatment of systemic lupus erythematosus (SLE), although much
remains unknown regarding the clinical utility of BAFF inhibition in SLE and other
autoimmune diseases. In the present review, we provide an overview of the knowledge …
Abstract
B-cell activating factor (BAFF), a member of the family of TNF-like cytokines, supports the survival and differentiation of B cells. The successful development of belimumab, a human antibody targeting soluble BAFF, has marked an important milestone in the development of biologic therapy for treatment of systemic lupus erythematosus (SLE), although much remains unknown regarding the clinical utility of BAFF inhibition in SLE and other autoimmune diseases. In the present review, we provide an overview of the knowledge concerning BAFF's role in murine and human B-cell development and maturation, as well as the clinical and mechanistic effects of BAFF inhibition in human SLE.
Springer